相关实验视频

Updated: Mar 17, 2026

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

巨细胞CBX4通过其SUMO E3联酶活性强化动脉样硬化

Zhenyu Zhao^1,2, Senping Xu^1,2, Jianying Ma³

¹Department of Vascular and Endovascular Surgery, The First Affiliated Hospital of Yangtze University, Jingzhou, 434000, China.

Cardiovascular drugs and therapy

|June 6, 2025

概括

染色体4 (CBX4) 通过增强缺氧诱导因子1-α (HIF-1α) 的相化来促进动脉样硬化. 降低CBX4水平可以缓解动脉样硬化病变,这表明CBX4是心血管疾病的潜在治疗点.

科学领域:

心血管生物学心血管生物学
疾病的分子机制.
基因组学和生物信息学

背景情况:

动脉样硬化 (AS) 是全球主要的心血管疾病和死亡原因之一.
目前对AS的治疗策略不足,需要新的方法.
基因组分析揭示了AS中的丰富的sumoylation通路和升高的染色盒4 (CBX4).

研究的目的:

为了研究CBX4在动脉样硬化进展期间巨细胞功能中的作用.
阐明CBX4参与AS的基础分子机制.
确定CBX4作为AS的潜在治疗点.

主要方法:

人类动脉样硬化组织的差异基因表达分析.
使用高脂肪饮食食的非脂蛋白E缺陷 (ApoE-/-) 小鼠来建模AS.
在小鼠中使用宏细胞特异性CBX4敲击和过度表达模型.
评估了CBX4和缺氧诱导因子1-alpha (HIF-1α) 之间的相互作用.

主要成果:

在动脉样硬化病变内的巨细胞中,CBX4表达显著上调.
巨细胞特异性CBX4敲击减弱了小鼠的AS发展.
过度表达CBX4会加剧AS的进展.
CBX4与HIF-1α直接相互作用,促进其相化并增强其转录活性.

结论:

通过CBX4介导的HIF-1α的sumoylation在加剧AS进展中起着至关重要的作用.
准CBX4为缓解动脉样硬化提供了一个有希望的治疗途径.
对CBX4sumoylation通路的进一步研究可能会为心血管疾病提供新的治疗方法.

关键词:

动脉样硬化是一种动脉样硬化.这就是CBX4 CBX4.这就是HIF-1α.巨细胞是一个巨细胞.这就是SUMOylation的作用.

更多相关视频

Quantification of Monocyte Chemotactic Activity In Vivo and Characterization of Blood Monocyte Derived Macrophages

Quantification of Monocyte Chemotactic Activity In Vivo and Characterization of Blood Monocyte Derived Macrophages

Published on: August 12, 2019

Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages

Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages

Published on: June 23, 2013

相关概念视频

Inflammation

Inflammation

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...